Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gotistobart vs Docetaxel in Metastatic NSCLC Progressed on PD-1/PD-L1 Inhibitors
NCT05671510Phase 3Active, not recruiting
- Sponsor
- OncoC4
- Start
- Jun 2023
- Primary completion
- Aug 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of gotistobart in non-small cell lung cancer (NSCLC), sponsored by OncoC4. Started Jun 2023; status: active, not recruiting.
02
Drugs
gotistobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05671510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05671510.